Rydapt (midostaurin)

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 I836	Acute Myelogenous Leukemia	FLT3 I836	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
FLT3-ITD mutation + RIPK1 expression	Acute Myelogenous Leukemia	FLT3-ITD mutation + RIPK1 expression	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
CEBPZ rearrangement + FLT3-TKD mutation	Acute Myelogenous Leukemia	CEBPZ rearrangement + FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
NPM1 mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	NPM1 mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3	midostaurin + cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials midostaurin + cytarabine / daunorubicin liposomal formulation Sensitive : C3
FLT3 positive	Acute Myelogenous Leukemia	FLT3 positive	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3	midostaurin Sensitive: C3 – Early Trials midostaurin Sensitive : C3
FLT3 N676K	Acute Myelogenous Leukemia	FLT3 N676K	Acute Myelogenous Leukemia	midostaurin Resistant: C4 – Case Studies midostaurin Resistant : C4	midostaurin Resistant: C4 – Case Studies midostaurin Resistant : C4
IDH1 R132H	Acute Myelogenous Leukemia	IDH1 R132H	Acute Myelogenous Leukemia	midostaurin Sensitive: C4 – Case Studies midostaurin Sensitive : C4	midostaurin Sensitive: C4 – Case Studies midostaurin Sensitive : C4
NPM1 exon 11 mutation	Acute Myelogenous Leukemia	NPM1 exon 11 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: C4 – Case Studies midostaurin Sensitive : C4	midostaurin Sensitive: C4 – Case Studies midostaurin Sensitive : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4
KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4

Rydapt (midostaurin)

Associations
(51)

Associations
(51)

Rydapt (midostaurin)

Associations(51)

Associations(51)

Associations
(51)

Associations
(51)